MDXG
Mimedx Group Inc
NASDAQ · Biotechnology
$5.15
+0.12 (+2.39%)
Open$5.02
Previous Close$5.03
Day High$5.19
Day Low$4.94
52W High$8.65
52W Low$4.89
Volume—
Avg Volume1.12M
Market Cap762.73M
P/E Ratio18.68
EPS$0.27
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+368.9% upside
Current
$5.15
$5.15
Target
$24.15
$24.15
$19.42
$24.15 avg
$35.38
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 346.66M | 313.72M | 209.33M |
| Net Income | 42.15M | 34.33M | 28.77M |
| Profit Margin | 12.2% | 11.6% | 13.8% |
| EBITDA | 59.30M | 50.98M | 34.33M |
| Free Cash Flow | — | — | 35.16M |
| Rev Growth | +10.5% | +10.5% | +3.6% |
| Debt/Equity | 0.10 | 0.10 | 0.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |